Dating as far back as 1986, recombinant IFNα received United States Food and Drug Administration (US FDA) approval for treating hematological malignancies, becoming the first therapeutic drug to treat cancer patients (97, 106, 107). This evidence concerns the gene IFNA1 and cancer.